Post by
juniper88 on Apr 14, 2021 11:50am
Something to keep in mind
First of all, I don't believe the sales of the legacy medicines is where the value is for Thera.
That said, traditionally Q1 sales are somewhat weak and it is hard to compare to the last Q4.
And comparing this year's Q1 to last year's Q1 you need to keep in mind that covid-19 hardly would have affected last year's sales (any lock downs as of Feb 28, 2020?), while this year's Q1 probably was the worst part of the pandemic so far. It probably affected sales.
Comment by
MHemorrhage on Apr 14, 2021 12:00pm
Also chiming in here to say the lockdowns this winter in Canada especially were even more significant than last year. I've been trading cannabis stocks for years and sales took a hit this last Q when they didn't throughout 2020